[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GR970300021T1 - Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof - Google Patents

Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Info

Publication number
GR970300021T1
GR970300021T1 GR970300021T GR970300021T GR970300021T1 GR 970300021 T1 GR970300021 T1 GR 970300021T1 GR 970300021 T GR970300021 T GR 970300021T GR 970300021 T GR970300021 T GR 970300021T GR 970300021 T1 GR970300021 T1 GR 970300021T1
Authority
GR
Greece
Prior art keywords
modulators
diagnostic
proteins
nucleic acids
body weight
Prior art date
Application number
GR970300021T
Other languages
English (en)
Inventor
Jeffrey M Friedman
Yiying Zhang
Ricardo Proenca
Margherita Maffei
Jeffrey L Halaas
Ketan Gajiwala
Stephen K Burley
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/292,345 external-priority patent/US6001968A/en
Priority claimed from US08/438,431 external-priority patent/US6429290B1/en
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of GR970300021T1 publication Critical patent/GR970300021T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
GR970300021T 1994-08-17 1997-07-30 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof GR970300021T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/292,345 US6001968A (en) 1994-08-17 1994-08-17 OB polypeptides, modified forms and compositions
US08/347,563 US5935810A (en) 1994-08-17 1994-11-30 Mammalian ob polypeptides capable of modulating body weight, corresponding nucleic acids, and diagnostic and therapeutic uses thereof
US08/438,431 US6429290B1 (en) 1994-08-17 1995-05-10 OB polypeptides, modified forms and derivatives
US08/483,211 US6309853B1 (en) 1994-08-17 1995-06-07 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PCT/US1995/010479 WO1996005309A2 (en) 1994-08-17 1995-08-17 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
GR970300021T1 true GR970300021T1 (en) 1997-07-30

Family

ID=27501568

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970300021T GR970300021T1 (en) 1994-08-17 1997-07-30 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Country Status (31)

Country Link
US (1) US6309853B1 (el)
EP (1) EP0777732B1 (el)
JP (1) JP3479080B2 (el)
CN (1) CN1162978B (el)
AP (1) AP815A (el)
BG (1) BG64710B1 (el)
BR (1) BR9508596A (el)
CA (1) CA2195955C (el)
CZ (1) CZ295018B6 (el)
DE (2) DE19531931A1 (el)
EE (1) EE04377B1 (el)
ES (1) ES2108663T3 (el)
FI (1) FI121709B (el)
GB (1) GB2292382B (el)
GE (1) GEP20022701B (el)
GR (1) GR970300021T1 (el)
HU (1) HU223563B1 (el)
IL (2) IL114987A (el)
IS (1) IS4416A (el)
LV (1) LV11868B (el)
MD (1) MD2311G2 (el)
MX (1) MX9701200A (el)
NO (2) NO323847B1 (el)
NZ (1) NZ291689A (el)
OA (1) OA10596A (el)
PL (1) PL183352B1 (el)
RO (1) RO121036B1 (el)
SI (1) SI9520090A (el)
SK (1) SK287191B6 (el)
TR (1) TR199501021A2 (el)
WO (1) WO1996005309A2 (el)

Families Citing this family (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5858967A (en) * 1995-01-20 1999-01-12 University Of Washington Appetite supression factor and related methods
US5554727A (en) * 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
AU4766196A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) * 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) * 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) * 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) * 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) * 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) * 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) * 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) * 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) * 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) * 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) * 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
WO1996031192A1 (de) * 1995-04-07 1996-10-10 Kuyus-Stiftung Kosmetische zusammensetzung zur behandlung von cellulite
US5614379A (en) * 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
ZA963530B (en) * 1995-05-05 1996-11-05 Hoffmann La Roche Recombinant obese (ob) proteins
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
AU5737696A (en) * 1995-05-08 1996-11-29 Chiron Corporation Nucleic acids for treating obesity
YU29596A (sh) * 1995-05-19 1998-07-10 Eli Lilly And Company Genski proizvodi koji regulišu gojaznost
EP0744408A3 (en) * 1995-05-26 1997-01-02 Eli Lilly And Company Rhesus ob protein and DNA
US6395509B1 (en) 1995-05-26 2002-05-28 Eli Lilly And Company DNA encoding Rhesus ob protein
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
EP0833835A4 (en) * 1995-06-22 1999-05-26 Lilly Co Eli OBESITY PROTEIN INTERMEDIATE PRODUCTS, THEIR PRODUCTION AND USE
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
EP0836479A2 (en) * 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes
DE69631605T2 (de) * 1995-08-17 2005-01-05 Amgen Inc., Thousand Oaks Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
CA2232193A1 (en) * 1995-09-19 1997-03-27 Brigitte Elisabeth Schoner Dna encoding medicinal proteins
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
ES2339846T3 (es) * 1995-11-22 2010-05-26 Amgen Inc. Metodo para aumentar la masa de tejido magro usando composiciones de proteina ob.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6225446B1 (en) 1995-12-06 2001-05-01 Schering Corporation Mutational variants of mammalian proteins
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US7632922B1 (en) 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
ATE267255T1 (de) * 1995-12-27 2004-06-15 Genentech Inc Ob proteinderivate mit verlängerter halbwertzeit
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6110707A (en) * 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
EP0877627A1 (en) * 1996-01-25 1998-11-18 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
KR19990087392A (ko) * 1996-03-01 1999-12-27 스티븐 엠. 오드레 개 ob 단백질 조성물 및 방법
EP0797999A3 (en) * 1996-03-26 2002-09-25 Eli Lilly And Company Formulations of obesity protein
EP0917469A1 (en) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Methods for inducing bone formation
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
EP0929310B1 (en) * 1996-06-04 2007-08-01 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with ob protein and ob antibodies
AR008765A1 (es) * 1996-06-06 2000-02-23 Smithkline Beecham Plc Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
EP0921820A4 (en) * 1996-06-20 2003-01-15 Merck & Co Inc GENE THERAPY OF OBESITY
CA2258755A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6630346B1 (en) * 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US20020110857A1 (en) * 1996-07-31 2002-08-15 Spurlock Michael E. Bovine leptin protein, antisense and antibody
US6277592B1 (en) * 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
AU4237797A (en) * 1996-08-30 1998-03-19 Amgen, Inc. Methods of increasing sensitivity of an individual to OB protein by upregula ting OB protein receptor
CN1230966A (zh) 1996-09-20 1999-10-06 赫彻斯特股份公司 勒帕素拮抗剂在用于治疗ii型糖尿病胰岛素耐受性中的用途
SE520392C2 (sv) * 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
WO1998016545A1 (en) * 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
NL1004559C2 (nl) * 1996-11-18 1998-05-19 Unilife Boter.
AU5654998A (en) * 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
CA2217698A1 (en) * 1996-12-20 1998-06-20 Eli Lilly And Company Anti-obesity proteins
CA2274799A1 (en) * 1996-12-20 1998-07-02 Eli Lilly And Company Anti-obesity proteins
NZ514145A (en) * 1996-12-20 2003-08-29 Amgen Inc OB fusion protein compositions and methods
EP1598054B1 (en) * 1997-04-15 2011-03-16 Csir Non-therapeutic methods of suppressing appetite
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
IL133136A0 (en) * 1997-06-06 2001-03-19 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP0996727B1 (en) * 1998-08-12 2003-01-08 Medical Research Council Gene conferring obese phenotype
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
CA2341412A1 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP2319928B9 (en) 1998-10-23 2014-04-16 Kirin-Amgen, Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU778939B2 (en) * 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins
EP1151102B1 (en) * 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
AU3910000A (en) * 1999-03-22 2000-10-09 Zymogenetics Inc. Improved methods for producing proteins in transformed (pichia)
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
CA2370539C (en) * 1999-04-23 2009-01-06 Massachusetts Institute Of Technology System and method for notating polymers
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
AU2001243512C1 (en) * 2000-03-08 2008-04-17 Massachusetts Institute Of Technology Heparinase III and uses thereof
JP2003530870A (ja) 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド Ａｐｏ−ＡＩ／ＡＩＩペプチド誘導体
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
DE60129695T2 (de) 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6443013B1 (en) * 2000-08-04 2002-09-03 Samsung Electronics Co., Ltd. Rotary test fixture
AU8628601A (en) * 2000-09-04 2002-03-22 Hyo-Joon Kim Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
ES2640975T3 (es) 2000-09-12 2017-11-07 Massachusetts Institute Of Technology Métodos y productos relacionados con heparina de peso molecular bajo
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
US7054758B2 (en) 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
KR100899970B1 (ko) 2001-02-19 2009-05-28 메르크 파텐트 게엠베하 Ｔ-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도
CN1330664C (zh) 2001-03-07 2007-08-08 默克专利有限公司 用于含杂合同种型抗体部分的蛋白质的表达技术
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ATE502053T1 (de) 2001-05-03 2011-04-15 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
NZ529267A (en) 2001-05-11 2006-05-26 Amgen Inc Peptides and related molecules that bind to tall-1
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
DE10145553B4 (de) * 2001-09-16 2006-06-08 Gene Architects Ag Nukleinsäure für einen Klonierungsvektor
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2002359288B2 (en) * 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
JP4547152B2 (ja) 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
ATE410459T1 (de) 2002-01-14 2008-10-15 Gen Hospital Corp Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2387003A1 (en) * 2002-05-21 2003-11-21 984012 Alberta Ltd. Method for improving efficiencies in livestock production
AU2003256613A1 (en) 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
AU2003254023A1 (en) 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
WO2004019866A2 (en) 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
ES2552226T3 (es) 2003-06-27 2015-11-26 DePuy Synthes Products, Inc. Reparación y regeneración de cartílago y hueso utilizando células derivadas posparto
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
WO2005012530A2 (en) 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
CA2537993C (en) 2003-09-05 2012-08-28 The General Hospital Corporation Dual phase drug release system
WO2005042475A2 (en) 2003-10-21 2005-05-12 Sention, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
DE10352510A1 (de) * 2003-11-07 2005-06-23 Forschungsinstitut Für Die Biologie Landwirtschaftlicher Nutztiere Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
WO2006014798A2 (en) * 2004-07-27 2006-02-09 Mount Sinai School Of Medicine Methods and compositions for using sax2
WO2006034296A2 (en) 2004-09-17 2006-03-30 Comentis, Inc. Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
ES2629397T3 (es) 2004-09-24 2017-08-09 Amgen Inc. Moléculas de Fc modificadas
CN101506355B (zh) 2004-09-24 2012-06-27 成血管细胞系统公司 多能扩增间充质前体细胞子代（memp）及其应用
EP2361970A1 (en) 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
US7307142B2 (en) * 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP1835924B1 (en) 2004-12-23 2013-08-21 Ethicon, Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
KR20080015079A (ko) 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
KR101446634B1 (ko) 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2007142667A2 (en) 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
PL1971681T3 (pl) 2005-12-16 2018-01-31 Depuy Synthes Products Inc Kompozycje oraz sposoby do hamowania niepożądanej odpowiedzi immunologicznej w przypadku transplantacji z brakiem zgodności tkankowej
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
EP1991264B1 (en) 2006-03-07 2015-01-07 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP5406710B2 (ja) 2006-05-19 2014-02-05 グライコフィ， インコーポレイテッド エリスロポエチン組成物
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
CA2840407A1 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
ES2717154T3 (es) 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
WO2009015314A2 (en) 2007-07-26 2009-01-29 Amgen Inc. Modified lecithin-cholesterol acyltransferase enzymes
US8299267B2 (en) 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
EP3115060A1 (en) 2008-04-18 2017-01-11 VaxInnate Corporation Deletion mutants of flagellin and methods of use
CN102099048A (zh) * 2008-05-21 2011-06-15 纽若泰兹公司 用于治疗与神经原纤维缠结有关的进行性认知障碍的方法
AU2009280042B2 (en) 2008-05-23 2015-06-04 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8815885B2 (en) 2008-09-15 2014-08-26 The Regents Of The University Of California Methods and compositions for modulating IRE1, SRC, and ABL activity
JP4966434B2 (ja) 2008-10-15 2012-07-04 バクスター・インターナショナル・インコーポレイテッド 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
NZ592113A (en) 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
US8491880B2 (en) 2008-12-10 2013-07-23 Mersana Therapeutics, Inc. Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
BRPI0923068B1 (pt) 2008-12-19 2021-05-25 Advanced Technologies And Regenerative Medicine, Llc Uso de células derivadas de tecido de cordão umbilical para tratar um paciente tendo uma doença, distúrbio ou injúria pulmonar
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
AU2009327382B2 (en) 2008-12-19 2014-07-17 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
BRPI1013409A2 (pt) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc células de tecido de cordão umbilical humano como terapia para doença de alzheimer
EP2416797A4 (en) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
WO2010148413A2 (en) 2009-06-19 2010-12-23 Medimmune, Llc Protease variants
MX353747B (es) 2009-08-17 2018-01-26 Memorial Sloan Kettering Cancer Center Star Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
CN112300172B (zh) 2009-09-04 2024-01-16 比奥根Ma公司 布鲁顿酪氨酸激酶抑制剂
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
CA2780205A1 (en) 2009-11-05 2011-05-12 Brown University Methods of treating elevations in mtor signaling
US20110136728A1 (en) * 2009-12-09 2011-06-09 Patricia Grasso Methods of increasing bone formation using leptin-related peptides
DK2509940T3 (en) 2009-12-10 2015-07-20 Univ California AMYLOID BINDING AGENTS
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN101812450B (zh) * 2010-04-28 2012-01-11 中国农业大学 辅助鉴定具有不同体重性状鸡的方法及其专用引物
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
WO2012058645A1 (en) 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
CA2827446C (en) 2011-02-14 2020-06-23 Allergan, Inc. Ester derivatives of bimatoprost compositions and methods
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
US20140221282A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
CN103732745A (zh) * 2011-06-15 2014-04-16 Nse产品公司 识别热量限制标记物和热量限制模拟物
WO2013009539A1 (en) 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
AU2011374879C1 (en) 2011-08-10 2018-06-14 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013063492A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
ES2676556T3 (es) 2011-12-23 2018-07-20 Depuy Synthes Products Llc Detección de células derivadas de tejido del cordón umbilical humano
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2013188452A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
EP2888239B1 (en) 2012-08-27 2018-11-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN104995192A (zh) 2012-09-26 2015-10-21 加利福尼亚大学董事会 Ire1的调节
PL2900230T3 (pl) 2012-09-27 2019-02-28 The Children's Medical Center Corporation Związki do leczenia otyłości i sposoby ich zastosowania
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP3985028A1 (en) 2013-02-06 2022-04-20 Celgene Corporation Modified t lymphocytes having improved specificity
WO2014153009A2 (en) 2013-03-14 2014-09-25 The Regents Of The University Of California, A California Corporation Thiosaccharide mucolytic agents
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
KR20150129735A (ko) 2013-03-15 2015-11-20 알러간, 인코포레이티드 렙틴 생성의 향상을 위한 비마토프로스트
RS57796B1 (sr) 2013-03-15 2018-12-31 Univ California Diestri acikličnog nukleozid fosfonata
CN111643663A (zh) 2013-03-15 2020-09-11 细胞基因公司 修饰的t淋巴细胞
WO2014149139A2 (en) 2013-03-15 2014-09-25 Verseon, Inc. Halogenopyrazoles as inhibitors of thrombin
ES2702182T3 (es) 2013-03-15 2019-02-27 Verseon Corp Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
EP3022207A4 (en) 2013-07-15 2016-12-07 Univ Texas COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER, NEUROLOGICAL ILLNESS, ETHANOL DENTURE, SCARENESS, DEPRESSION AND NEUROPATHIC PAIN
HRP20201302T1 (hr) 2013-08-19 2021-02-05 The Regents Of The University Of California Spojevi i metode za liječenje epileptičnog poremećaja
WO2015031799A1 (en) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Scintillator nanocrystal-containing compositions and methods for their use
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
PL3074033T3 (pl) 2013-11-26 2019-08-30 The Children's Medical Center Corporation Związki do leczenia otyłości i sposoby ich zastosowania
ES2713196T3 (es) 2013-12-11 2019-05-20 Biogen Ma Inc Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
US9809577B2 (en) 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
CA2934850C (en) 2013-12-23 2022-12-06 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
PL3094353T3 (pl) 2014-01-15 2020-09-07 Medimmune, Llc Przeciwciała swoiste pod kątem RSV i ich funkcjonalne części
KR20160124835A (ko) 2014-02-20 2016-10-28 알러간, 인코포레이티드 베타-클로로시클로펜탄의 친수성 에스테르 프로드럭의 사용에 의해 감소된 중앙 각막 비후
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
AU2015259173B2 (en) 2014-05-13 2019-09-05 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
SG11201701111SA (en) 2014-08-12 2017-03-30 Anthrogenesis Corp Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
AU2015317972B2 (en) 2014-09-15 2019-10-17 The Regents Of The University Of California Nucleotide analogs
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
EP3201192B1 (en) 2014-10-02 2019-08-21 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
KR20230152844A (ko) 2015-02-25 2023-11-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 질환을 치료하기 위한 5ht 작용제
PL3261639T3 (pl) 2015-02-27 2022-12-19 Verseon International Corporation Podstawione związki pirazolowe jako inhibitory proteazy serynowej
EP3262040A4 (en) 2015-02-27 2018-09-12 The Regents of The University of California Small molecules that enable cartilage rejuvanation
EP3280708B1 (en) 2015-04-10 2021-09-01 Araxes Pharma LLC Substituted quinazoline compounds and methods of use thereof
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
EP3307732A1 (en) 2015-06-10 2018-04-18 Biogen MA Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN105132566A (zh) * 2015-09-21 2015-12-09 上海中优生物高科技有限责任公司 毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3359647A1 (en) 2015-10-08 2018-08-15 Neurona Therapeutics Inc. Neural precursor cell populations and uses thereof
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
CN119241632A (zh) 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
CA3002907A1 (en) 2015-10-23 2017-04-27 Sunesis Pharmaceuticals, Inc. Heterocyclic pdk1 inhibitors for use to treat cancer
WO2017087528A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
IL260208B2 (en) 2015-12-24 2024-04-01 Univ California Cftr regulators and methods of use thereof
PL3394046T3 (pl) 2015-12-24 2022-06-13 The Regents Of The University Of California Regulatory cftr i sposoby ich zastosowania
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
ES2886935T3 (es) 2016-04-25 2021-12-21 Forma Therapeutics Inc Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
EP3448519A4 (en) 2016-04-29 2020-01-22 Board Of Regents, The University Of Texas System SIGMA RECEIVER BINDERS
SG11201809237RA (en) 2016-05-12 2018-11-29 Anacor Pharmaceuticals Inc Oxaborole esters and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
KR20190035769A (ko) 2016-07-21 2019-04-03 바이오젠 엠에이 인코포레이티드 브루톤 타이로신 카이나제 저해제의 석신에이트 형태 및 조성물
JP6994018B2 (ja) 2016-07-26 2022-01-14 バイオマリン ファーマシューティカル インコーポレイテッド 新規アデノ随伴ウイルスキャプシドタンパク質
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
ES2916335T3 (es) 2016-10-20 2022-06-30 Celgene Corp Receptores de antígeno quimérico heterodimerizable basados en cereblon
KR20190095355A (ko) 2016-12-15 2019-08-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암의 치료를 위한 조성물 및 방법
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
EP3694860A1 (en) 2017-10-10 2020-08-19 Syros Pharmaceuticals, Inc. Pyrrolotriazine compounds and methods of inhibiting tam kinases
AU2019209470A1 (en) 2018-01-16 2020-08-13 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP7590183B2 (ja) 2018-03-13 2024-11-26 武田薬品工業株式会社 血漿カリクレインのインヒビターとしての置換されたイミダゾピリジン及びその使用
JP2021522811A (ja) 2018-05-09 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド フェニルケトン尿症の治療方法
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP3849620A4 (en) 2018-09-10 2022-08-17 The Regents of the University of California DITHIOL SACCHARIDE MUCOLYTICS AND USES THEREOF
WO2020252487A1 (en) 2019-06-14 2020-12-17 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
CN114667289A (zh) 2019-09-18 2022-06-24 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4136091B1 (en) 2020-04-17 2025-05-28 Takeda Pharmaceutical Company Limited Forms and compositions of inhibitors of plasma kallikrein
WO2021211938A1 (en) 2020-04-17 2021-10-21 Shire Human Genetic Therapies, Inc. Solid forms of inhibitors of plasma kallikrein
CN117396474A (zh) 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂
EP4308227A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Imidazopyridinyl inhibitors of plasma kallikrein
MX2023011014A (es) 2021-03-17 2023-12-06 Takeda Pharmaceuticals Co Inhibidores de heteroarílo de la calicreína plasmática.
WO2022197789A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Polycyclic inhibitors of plasma kallikrein
EP4308229A1 (en) 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein
TW202321278A (zh) 2021-08-06 2023-06-01 美商西建公司 用於選擇性降解工程蛋白質的組合物和方法
EP4337667A4 (en) 2022-07-21 2025-04-23 Antiva Biosciences Inc COMPOSITIONS AND DOSAGE FORMS FOR THE TREATMENT OF HPV INFECTION AND HPV-INDUCED NEOPLASIA
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use
WO2024059186A1 (en) 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
USRE31006E (en) 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3650090A (en) 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
EP0043718B1 (en) 1980-07-07 1984-11-28 National Research Development Corporation Improvements in or relating to cell lines
US4341761A (en) 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4466917A (en) 1981-02-12 1984-08-21 New York University Malaria vaccine
US4493890A (en) 1981-03-23 1985-01-15 Miles Laboratories, Inc. Activated apoglucose oxidase and its use in specific binding assays
US4451570A (en) 1981-03-26 1984-05-29 The Regents Of The University Of California Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line
US4399121A (en) 1981-11-04 1983-08-16 Miles Laboratories, Inc. Iodothyronine immunogens and antibodies
US4427783A (en) 1981-12-14 1984-01-24 Hoffmann-La Roche Inc. Immunoassay of thymosin α1
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
EP0347041A3 (en) 1988-05-13 1990-11-22 Amgen Inc. Compositions and method for treating or preventing infections in animals
IL91765A0 (en) 1988-09-26 1990-06-10 Salk Inst Biotech Ind Mixed feed recombinant yeast fermentation
US5102789A (en) 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
WO1990014092A1 (en) 1989-05-18 1990-11-29 Cell Genesys, Inc. Single-strand site-directed modification of mammalian genes in vivo
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006667A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0779362T4 (da) 1989-12-22 2012-07-30 Serono Lab DNA-konstruktioner til aktivering og modifikation af endogene geners ekspression
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
ZA924674B (en) 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
EP0566410A3 (en) 1992-04-17 1994-08-24 Sankyo Co Derivatives of adipogenesis inhibitory factor, their preparation and their use
ES2252732T3 (es) 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
JPH08500483A (ja) * 1992-06-19 1996-01-23 ジョスリン ダイアビーティーズ センター インコーポレイテッド 糖尿遺伝子ｒａｄ：２型糖尿病特異性遺伝子
CA2148484A1 (en) 1992-11-13 1994-05-26 Stewart Lyman Novel cytokine designated elk ligand
US5574018A (en) 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
AU4766196A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
JPH08333394A (ja) 1995-04-03 1996-12-17 Takeda Chem Ind Ltd ラット肥満遺伝子、その遺伝子産物およびその製造法
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
YU29596A (sh) 1995-05-19 1998-07-10 Eli Lilly And Company Genski proizvodi koji regulišu gojaznost
EP0744408A3 (en) 1995-05-26 1997-01-02 Eli Lilly And Company Rhesus ob protein and DNA
EP0759441A3 (en) 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
EP0836479A2 (en) 1995-06-30 1998-04-22 Eli Lilly And Company Methods for treating diabetes
CA2232193A1 (en) 1995-09-19 1997-03-27 Brigitte Elisabeth Schoner Dna encoding medicinal proteins
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
JP2000504318A (ja) 1996-01-19 2000-04-11 イーライ・リリー・アンド・カンパニー 肥満症タンパク質製剤
EP0784981A3 (en) 1996-01-19 1999-03-03 Eli Lilly And Company Obesity protein formulations
EP0784979A3 (en) 1996-01-19 1999-03-03 Eli Lilly And Company Obesity protein formulations
AU1705197A (en) 1996-01-19 1997-08-11 Eli Lilly And Company Obesity protein formulations
EP0797999A3 (en) 1996-03-26 2002-09-25 Eli Lilly And Company Formulations of obesity protein

Also Published As

Publication number Publication date
US6309853B1 (en) 2001-10-30
FI121709B (fi) 2011-03-15
IL162093A0 (en) 2005-11-20
OA10596A (en) 2002-06-26
MD2311G2 (ro) 2004-08-31
RO121036B1 (ro) 2006-11-30
EE9700030A (et) 1997-08-15
CA2195955C (en) 2012-03-13
LV11868B (en) 1998-01-20
MX9701200A (es) 1998-05-31
GB2292382A (en) 1996-02-21
MD970100A (en) 1998-04-30
BG101228A (en) 1997-09-30
BG64710B1 (bg) 2005-12-30
HK1001495A1 (en) 1998-06-19
SK22197A3 (en) 1998-02-04
NZ291689A (en) 2000-01-28
NO326376B1 (no) 2008-11-17
JPH09506264A (ja) 1997-06-24
EP0777732A1 (en) 1997-06-11
JP3479080B2 (ja) 2003-12-15
LV11868A (lv) 1997-10-20
DE777732T1 (de) 1998-01-29
SI9520090A (sl) 1998-08-31
CN1162978B (zh) 2010-06-16
NO323847B1 (no) 2007-07-09
SK287191B6 (sk) 2010-02-08
WO1996005309A2 (en) 1996-02-22
HU223563B1 (hu) 2004-09-28
IS4416A (is) 1997-01-17
TR199501021A2 (tr) 1996-06-21
CN1162978A (zh) 1997-10-22
GB2292382B (en) 1997-07-16
ES2108663T1 (es) 1998-01-01
FI970656A0 (fi) 1997-02-17
CZ46097A3 (en) 1997-11-12
EE04377B1 (et) 2004-10-15
CA2195955A1 (en) 1996-02-22
ES2108663T3 (es) 2012-02-17
AP9700919A0 (en) 1997-01-31
NO970683L (no) 1997-04-16
DE19531931A1 (de) 1996-03-07
FI970656A7 (fi) 1997-02-17
NO20065287L (no) 1997-04-16
PL319021A1 (en) 1997-07-21
BR9508596A (pt) 1997-10-21
IL114987A (en) 2004-07-25
GEP20022701B (en) 2002-05-27
NO970683D0 (no) 1997-02-14
GB9516947D0 (en) 1995-10-18
WO1996005309A3 (en) 1996-03-21
HUT78052A (hu) 1999-07-28
AP815A (en) 2000-03-10
EP0777732B1 (en) 2011-09-28
PL183352B1 (pl) 2002-06-28
CZ295018B6 (cs) 2005-05-18
IL114987A0 (en) 1995-12-08
MD2311F2 (en) 2003-11-30

Similar Documents

Publication Publication Date Title
IL162093A0 (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
NZ227177A (en) Vectors and dna compounds for the expression of human protein c
AU9383098A (en) Novel targeted contrast agents for diagnostic and therapeutic use
IL117725A0 (en) Radiolabeled peptides for diagnosis and therapy
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
EP0831793A4 (en) PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
AU4553793A (en) Use of p97 and iron binding proteins as diagnostic and therapeutic agents
IL114331A0 (en) Medical use of bromelain
AU4713497A (en) Use of hollow microcapsules in diagnosis and therapy
AU2832195A (en) Nucleic acid-binding oligomers for therapy and diagnosis
AU3329895A (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU3698595A (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU738966C (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
TJ425B (en) Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
EP0787795A4 (en) HUMAN TOPOISOMERASE I DNA VARIANT PROTEIN
KR970705631A (ko) 핵산과 지방에 대응하는, 체중 모듈레이터, 및 진단과 그의 치료적 이용(modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof)
PL319344A1 (en) Gene of human galactokinase
HK1014154A (en) Human therapeutic uses of bpi protein products
GB9501978D0 (en) Nucleic acids, proteins and their use in therapy
GB9523019D0 (en) Microencapsulated DNA for vaccination and gene therapy
IL149185A0 (en) Nucleic acids of the human abc1 gene and their therapeutic and diagnostic application
PL319345A1 (en) Gene of human galactokinase